OncoMatch/Clinical Trials/NCT04271644
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Is NCT04271644 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BCMA CAR-T cells for multiple myeloma.
Treatment: BCMA CAR-T cells — This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) any tested (cell membrane BCMA expression)
Evidence for cell membrane BCMA expression
Disease stage
Required: Stage RELAPSED, REFRACTORY
Demographics
Prior therapy
Must have received: chemotherapy
Failed to standard chemotherapy regimens
Must have received: hematopoietic stem cell transplant
Relapse after hematopoietic stem cell transplantation
Lab requirements
Kidney function
creatinine clearance≤2 x uln
Liver function
alt/ast≤3 x uln and bilirubin≤2 x uln
Cardiac function
left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04271644 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and hematopoietic stem cell transplant.
Does this trial require TNFRSF17?
Yes, TNFRSF17 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages